Anuh Pharma Limited (NSE:ANUHPHR)
India · Delayed Price · Currency is INR | Market Cap | 7.77B -20.4% |
| Revenue (ttm) | 7.68B +22.4% |
| Net Income | 418.22M -16.8% |
| EPS | 4.17 -16.7% |
| Shares Out | n/a |
| PE Ratio | 18.57 |
| Forward PE | n/a |
| Dividend | 1.50 (1.84%) |
| Ex-Dividend Date | Aug 14, 2025 |
| Volume | 48,322 |
| Average Volume | 44,910 |
| Open | 78.90 |
| Previous Close | 77.38 |
| Day's Range | 75.21 - 78.90 |
| 52-Week Range | 69.27 - 114.90 |
| Beta | n/a |
| RSI | 44.31 |
| Earnings Date | Feb 6, 2026 |
About Anuh Pharma
Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-bacterial, anti-asthmatics, anti-diabetics, intermediates, expectorant, quinolones, anti-malarial, anti-gout, anti-biotic, anti-platelet, and antihistamines; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic. The company also develops products, such as coagulants, gastrointestinal, anti convulsants, and cholesterol drugs. It a... [Read more]
Financial Performance
In fiscal year 2025, Anuh Pharma's revenue was 6.62 billion, an increase of 2.24% compared to the previous year's 6.47 billion. Earnings were 473.52 million, a decrease of -21.16%.
Financial StatementsNews
Anuh Pharma Secures EDQM Certificate of Suitability for Sulfadimethoxine
Anuh Pharma Limited on Friday announced that it has received the Certificate of Suitability (CEP) from the European Directorate for...
Anuh Pharma inaugurates new manufacturing block to boost capacity by 200 MT annually
Anuh Pharma Limited announced on Tuesday that it has inaugurated its new manufacturing block, INT-1A, at its facility in Tarapur, Boisar, Maharashtra. The inauguration took place on July 15, 2025, the...